Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine A concentration-inhibition analysis and comparison with human data

Peng Hsiao, Lucy Sasongko, Jeanne M. Link, David A. Mankoff, Mark Muzi, Ann C. Collier and Jashvant D Unadkat

Department of Pharmaceutics (PH, LS, JDU), Division of Nuclear Medicine (JML, DAM, MM) and Department of Medicine (ACC), University of Washington, Seattle, WA 98195

Running Title Page

Running Title

P-gp transport of verapamil across the rat and human BBB

Corresponding Author

Jashvant (Jash) Unadkat, Ph.D.

Professor, School of Pharmacy

Department of Pharmaceutics

University of Washington, Box 357610

Seattle, WA 98195

Phone (206) 543-9434

FAX (206) 543-3204

Email: jash@u.washington.edu

Number of text pages: 26

Number of figures: 6

Number of references: 24

Abstract: 248

Introduction: 509

Discussion: 1514

Abbreviations: P-gp, P-glycoprotein; BBB, blood-brain-barrier; CsA, Cyclosporine A;

PET, positron emission tomography.

Recommended section: Absorption, Distribution, Metabolism, and Excretion

ABSTRACT

To predict the magnitude of P-glycoprotein (P-gp) based drug interactions at the human blood brain barrier (BBB), rodent sudies are routinely conducted where P-gp is chemically inhibited. For such studies to be predictive of interactions at the human BBB, the plasma concentration of the P-gp inhibitor must be comparable to that observed in the clinic. Therefore, we determined the *in vivo* EC50 of P-gp inhibition at the rat BBB using verapamil as a model P-gp substrate and cyclosporine A (CsA) as the model P-gp inhibitor. Under isoflurane anesthesia, male Sprague Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to ~12 μM. Then, an i.v. tracer dose of [^{3}H]-verapamil was administered and 20 min. after verapamil administration the animals were sacrificed for determination of blood, plasma, and brain [^{3}H]-radioactivity by scintillation counting. The percent increase in the brain:blood [^{3}H]-radioactivity (relative to 0 μM CsA), was described by the Hill equation with Emax 1290%, EC50 7.2 μM, and γ 3.8. Previously, using ^{11}C-verapamil, we have shown that the human brain:blood [^{11}C]-radioactivity was increased by 79% at 2.8 μM CsA blood concentration. At an equivalent CsA blood concentration, the rat brain:blood [^{3}H]-radioactivity was increased by a remarkably similar extent of 75%. This is the first time that an *in vivo* CsA EC50 of P-gp inhibition at the rat BBB has been determined and the magnitude of such inhibition compared between the rat and the human BBB at the same blood CsA concentration.

INTRODUCTION

The blood brain barrier (BBB) modulates the entry of drugs and xenobiotics into the central nervous system (CNS). This barrier is composed of endothelial cells that form tight junctions. Therefore, hydrophilic drugs have limited capacity to enter the CNS, except by a carrier mechanism that can transport the drug across the BBB. Although lipophilic drugs are capable of readily diffusing across the BBB, several efflux transporters present in this barrier prevent or reduce the entry of these drugs into the CNS (Bart et al., 2000; Bendayan et al., 2002; Demeule et al., 2002; Golden and Pollack, 2003). Prominent amongst these is P-glycoprotein (P-gp), an ABC transporter encoded by the multi-drug resistance 1 (*MDR1*) gene (Schinkel et al., 1996). Numerous studies in the P-gp knock-out mouse model (mdr1ab(-/-)) have revealed that ablation of P-gp has a significant effect on absorption, distribution and elimination of drugs, with the largest effect occurring on the distribution of drugs across the BBB and into the central nervous system (CNS). For example, compared to the wild type mouse, the brain:blood concentration ratio of the anti-HIV protease inhibitors, nelfinavir, indinavir, and saquinavir, are increased 7 to 36-fold (Kim et al., 1998), anti-cancer taxanes, paclitaxel and docetaxel are increased 6 to 28-fold (Kemper et al., 2003; Kemper et al., 2004a; Kemper et al., 2004b), digoxin is increased 10-fold(Mayer et al., 1997) , while that of verapamil is increased 8.5-fold (Hendrikse et al., 1998). Similar data have been obtained in mice and rats where P-gp has been chemically ablated with selective inhibitors of P-gp such as PSC 833 (Valspodar), GF120918 (Elacridar), and LY335979 (Zosuquidar) (Kusuhara et al., 1997; Mayer et al., 1997; Kemper et al., 2003; Kemper et al., 2004a;

Kemper et al., 2004b). For example, the brain:blood ratio of verapamil is increased 9.6-fold when the rat is pretreated with cyclosporine A (CsA) (Hendrikse et al., 1998).

Although rodent studies make a compelling case for the importance of P-gp at the BBB in the CNS distribution of drugs, their ability to predict the magnitude of P-gp based drug interactions at the human BBB has not been investigated. We postulate that the mdr1a/b(-/-) mouse or chemical ablation of P-gp at the rodent BBB are likely to overestimate the magnitude of clinically relevant P-gp based interactions at the human BBB. To better predict such drug interactions, we propose that the concentration of the P-gp inhibitor used in the rodent studies be comparable to that observed in the clinic. Therefore, we determined the *in vivo* EC50 of inhibition of P-gp activity at the rat BBB using verapamil as a model P-gp substrate and cyclosporine A (CsA) as the model P-gp inhibitor. Then, we compared the magnitude of inhibition of P-gp at the rat and the human BBB at an identical blood CsA concentration. The human data were previously obtained in our laboratory (Sasongko et al., 2005) using virtually identical experimental protocol (^{11}C-verapamil as the P-gp substrate) as that used in the rat, except that the brain distribution of ^{11}C-verapamil radioactivity was quantified using the noninvasive but quantitative methodology, positron emission tomography (PET).

MATERIALS AND METHODS

Materials. [3H]-(+/-) verapamil (80 Ci/mmol) and [14C]-sucrose (600 mCi/mmol) were purchased from American Radiolabeled Chemicals (St Louis, MO). Cyclosporine A (Sandimune, 50 mg/mL) was purchased from Abbott Lab, Chicago, IL. Verapamil metabolites D617 (3,4-dimethoxy-α-[3-(methylamino)propyl]-α-(1-

methylethyl)benzeneacetonitrile), D717 (4-hydroxy-3-methoxy-α-[3-(methylamino)propyl]-α-(1-methylethyl)benzeneacetonitrile), D702 (α-[3-[[2-(4-hydroxy-3-methoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-α-(1-methylethyl)benzeneacetonitrile), D703 (α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-4-hydroxy-3-methoxy-α-(1-methylethyl)benzeneacetonitrile) were a gift from Abbott Lab (formally Knoll AG, Ludwigshafen, Germany). All other reagents were of the highest grade available from commercial sources.

Animals. Male Sprague Dawley rats (8~10 wks, ~300g) were purchased from Charles River Laboratories, Inc. (Wilmington, MA) and housed in a temperature and humidity controlled room with a 12-h light/dark cycle, with free access to food and water. The experimental protocol was approved by the Institutional Animal Care and Use Committee of the University of Washington. All experimental procedures were conducted according to the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC, 1996).

Experimental protocol. Under isoflurane anesthesia (5% induction, 1~1.5% maintenance at 1.0 L/min), each animal was cannulated in either the left or right femoral artery and vein. Anesthesia was maintained throughout the experiment. The anesthesia plane and the condition of the animal were evaluated by routine tail/toe pinching test, respiration rate, and the palpebral reflex test. CsA (or saline) (0, 2.3, 5.0, 7.0, and 10.1 mg/kg in 0.1mL) was administered as an i.v. bolus, followed by a constant rate i.v. infusion (0, 3.24, 6.48, 9.0, and 12.96 mg/kg/0.5mL/h) via the femoral vein to achieve

pseudo steady-state blood CsA concentration of 0, ~ 3.0 (3.6), 6.0 (7.2), 8.3 (10), 12.0 (14.4) µM (µg/mL) respectively. CsA blood samples (~0.5 mL) were collected in heparanized tubes via the femoral artery at 0 (preCsA), 30, 45, 60, and 80 min. Hematocrit in each blood sample (~50 µL) was determined immediately following each blood draw. At 60 min, a tracer i.v. bolus dose of [3H]-verapamil (43 µCi/kg, 0.24 µg/kg) was administered via the femoral vein. At 79 min, a tracer i.v. bolus dose of [14C]-sucrose (3.3 µCi/kg, 1.9 µg/kg), a brain vascular volume marker, was administered via the femoral vein. Immediately following the 80 min blood draw (i.e. 20 min after [3H]-verapamil administration), the animal was sacrificed by decapitation and the brain harvested. This time point was chosen to minimize the metabolism of verapamil, and because previously reported studies (Hendrikse et al., 1998; Bart et al., 2003; Luurtsema et al., 2005) indicated that such a duration was adequate to reach pseudoequilibrium between the brain and plasma. Blood CsA concentrations were determined within 24 h by HPLC/UV (Laboratory of Medicine at UWMC), while the brain, blood, and plasma samples were stored at -20°C until analysis by HPLC and/or scintillation counting.

Blood and brain tissue processing: Each blood sample (50 µL) was incubated at 50°C with 1 mL of Biolsol™ (National Diagnostics, Atlanta Georgia) for 3 h in a 20 mL scintillation vial. Then, 30% H_2O_2 (300 µL) was added to the vial to bleach the solution. One hour later, scintillation fluid (10 mL) was added to the vial and stored at room temperature for 5 days to allow any chemical quenching to dissipate prior to scintillation counting. Previous experiments with blood samples spiked with known quantities of radioactivity showed that this time was sufficient to dissipate chemical quenching. Brain sample (0.7-1 g) was homogenized, with PBS (100 µL PBS per 100 mg brain). The

brain/PBS homogenate (200 µL) were then processed and counted as described above.

All blood and brain samples were processed and counted in triplicate.

Metabolite analysis. Non-radioactive standards of verapamil (5.6 ng/mL) and

verapamil metabolites (D617, D717, D702, D703; 2.0 ng/mL) were added to each

brain/PBS homogenate (900 µL). The spiked homogenate was then precipitated with 1:1

acetonitrile followed by centrifugation at 20,800 g and filtered through a 0.2 µm filter.

The filtrate was then injected (500 µl) onto a Zorbax SB-C8 HPLC column (5µm, 4.6 ×

250 mm, Agilent) and eluted at 1 mL/min with a gradient mobile phase consisting of

100% acetonitrile (mobile phase A) and 30 mM ammonium acetate (pH 5.0; mobile

phase B). The gradient was adjusted linearly as follows: 25% A: 75% B for the first 3

min, 35% A: 65% B from 3 to 7 min, 50% A: 50% B from 7 to 12 min, maintained at this

composition from 12 to 20 min, and then 90% A: 10% B from 20 to 20.5 min to rapidly

elute any highly retained peaks. Then, from 20.5 to 21 min the gradient was reduced

linearly to 25% A: 75% B, and was subsequently maintained at this composition up to 25

min for re-equilibration. The nonradioactive spiked standards were detected at 229 nm.

Fractions of HPLC effluent were collected at 1 min intervals over 25 min to separate

verapamil and its metabolites that had retention times of 9.5 min (D617), 12 min (D717),

17 min (D702/D703) and 20 min (verapamil). The collected factions were counted using

scintillation counter.

Each plasma sample (850 µL) was spiked with non-radioactive standards of

verapamil and verapamil metabolites (same concentrations as the brain homogenate),

precipitated with 1:1 acetonitrile, centrifuged at 20,800 g and then filtered through a 0.2

µm filter. The filtrate (500 µl) was then analyzed by HPLC and the fractions were

collected for counting as described above. Metabolite content in blood was not determined, due to limited sample volume and the analytical challenge for conducting such analysis.

Data Analysis. The average of CsA blood concentration at 60 and 80 min after beginning CsA infusion was computed for each animal and averaged across the animals studied. This value (mean ± SD) is henceforth referred to as the pseudo steady-state blood CsA concentration. The brain: blood ratio of total $[^3H]$-radioactivity was adjusted for vascular contamination. The vascular volume (μL/g) was calculated as the ratio of the $[^{14}C]$-sucrose radioactivity per gram of brain and the $[^{14}C]$-sucrose radioactivity per mL of blood (Fenstermacher et al., 1981). The brain: plasma ratio of $[^3H]$-verapamil or the $[^3H]$-metabolites was also computed. Using nonlinear regression (WinNonlin®; Pharsight Corporation), the Hill equation was fit to the percent increase in the brain: blood ratio of total $[^3H]$-radioactivity or brain: plasma ratio of $[^3H]$-verapamil as a function of blood CsA concentration. Unless otherwise stated, data are presented as mean ± S.D. Student's t test or analysis of variance, were used to determine the statistical significance of difference ($p < 0.05$) between experimental groups.

Comparison with previously published human data. We have previously published a study (Sasongko et al., 2005) in which we determined the inhibition of ^{11}C-verapamil P-gp transport across the human BBB by CsA. In this study, we used the same experimental conditions as that employed in the above rat study, except that the distribution of ^{11}C-radioactivity in the brain was measured at a single pseudo steady-state blood CsA concentration of 2.8 μM using PET. Briefly, ^{11}C-verapamil (~ 0.2 mCi/kg) was administered to healthy volunteers ($n = 12$, 6 females and 6 males) as an IV infusion

over ~ 1 min before and after at least 1 h infusion of CsA (2.5 mg/kg/hr). Arterial blood

samples and brain PET images were obtained at frequent intervals over 45 min. Both

blood and plasma radioactivity contents were determined in each verapamil sample. The

content of verapamil and its metabolites in each plasma sample was determined by a

rapid solid-phase extraction method. The brain uptake of ^{11}C-radioactivity (brain:blood

at 45 min) was determined in the presence and absence of CsA. For additional details on

the methods, the reader is referred to Sasongko et al, 2005 (Sasongko et al., 2005).

RESULTS

Changes in CsA blood concentration did not significantly affect the estimate of the brain vascular volume (data not shown) and therefore, data from all the CsA groups were pooled and compared with that obtained in the absence of CsA (control). Estimate of the brain vascular volume in the CsA (24.4 ± 9 µL/g) and the control (26.3 ± 10 µL/g) groups were not significantly different. The blood:plasma ratio of total [3H]-radioactivity ([3H]-verapamil and [3H]-metabolites) was 0.75 ± 0.1 and was independent of CsA blood concentration (data not shown).

Except at the highest CsA infusion rate, the targeted pseudo steady-state blood CsA concentrations were achieved during the 20 min period after [3H]-verapamil administration. These concentrations were 2.9 ± 0.3 (n=5), 5.8 ± 0.2 (n=5), 9.3 ± 1.7 (n=5) and 17.3 ± 3.2 (n=6) µM at infusion rate 3.24, 6.48, 9.0, and 12.96 mg/kg/0.5mL/h, respectively (Fig. 1). The highest blood CsA concentration achieved (17.3 ± 3.2 µM) differed from the expected (12 µM) most likely due to nonlinearity in the pharmacokinetics of CsA.

At 20 min post [3H]-verapamil administration, the brain:blood [3H]-radioactivity (corrected for vascular volume) was 0.79 ± 0.1 (n=10), 1.39 ± 0.2 (n=5), 2.87 ± 0.4 (n=5), 7.06 ± 0.6 (n=5), and 9.19 ± 1.4 (n=6) at 0, 2.9, 5.8, 9.3, and 17.3 µM blood CsA concentration, respectively (Figure 2). The percent increase in the brain:blood [3H]-radioactivity, expressed relative to that in the control group (absence of CsA), increased as the blood CsA concentration increased and appeared to reach a plateau at blood CsA greater than 15 µM (Figure 3A). The Hill equation (Figure 3A) was fit to these data using

nonlinear regression (uniform weighting) and yielded the following estimates (% CV of the estimate): Emax 1290% (7.1%), EC50 7.2 µM (7.3%), and γ 3.8 (22.5%).

While the brain: blood ratio for the [³H]-radioactivity was significantly increased by CsA, the total [³H]-radioactivity in the blood or plasma was independent of blood CsA concentration (data not show). Furthermore, CsA did not significantly (p>0.05) affect [³H]-verapamil content in the plasma at 20 min post-[³H]-verapamil administration (46.6 ± 8.7%, 46.8 ± 8.9%, 46.7 ± 7.6%, 40.9 ± 6.6%, and 38.6 ± 8.7% of total plasma radioactivity at 0, 2.9, 5.8, 9.3, and 17.3 µM blood CsA concentrations respectively). [³H]-radiolabeled D617, D717, and D702/D703 (Fig 4) concentrations in the plasma were below those that could be quantified with confidence. Due to high structural similarity, metabolites D702 and D703 could not be chromatographically separated and therefore are reported as combined fractions. An appreciable amount of unidentified [³H]-metabolite(s) were measured in the plasma. These unidentified [³H]-metabolite(s) collectively had a retention time of approximately 3 min and eluted as a relatively broad peak (2-5 min). This metabolite(s) is henceforth referred to as the unknown [³H]-metabolite(s). The plasma content of this unknown [³H]-metabolite(s) was not significantly (p>0.05) affected by CsA (47.7 ± 9.9%, 45.9 ± 11.3%, 46.1 ± 8.3%, 50.7 ± 6.1%, and 52.8 ± 8.4% of total plasma radioactivity at 0, 2.9, 5.8, 9.3, and 17.3 µM blood CsA concentrations respectively).

In the absence of CsA, and 20 min post [³H]-verapamil administration, the brain content of [³H]-verapamil and the unknown [³H]-metabolite(s) was 46.3 ± 9.7% and 45.8 ± 10.9% respectively. As expected, the increase in brain [³H]-radioactivity content produced by CsA was predominantly due to a significant (p<0.05) increase in the brain

[^{3}H]-verapamil content (Fig. 5). The percent increase in the brain:plasma [^{3}H]-verapamil, expressed relative to that in the control group, increased as the blood CsA concentration increased. The fit of the Hill equation to these data, using nonlinear regression (uniform weighting; Fig. 3B), resulted in the following estimates (% CV of the estimate): Emax 2630% (7.1%), EC50 7.9 µM (7.1%), and γ 3.7 (19.7%). In contrast to [^{3}H]-verapamil, the brain content of the unknown [^{3}H]-metabolite(s) was not significantly altered by CsA ($P > 0.05$) but that of [^{3}H]-D702/D703 increased as blood CsA concentration increased (Fig. 5 inset). The latter was not expressed as brain:blood ratio as the blood concentrations of D702/D703 were negligible and could not be determined with confidence. The brain concentrations of the other metabolites (D617, D717) were below those that could be quantified with confidence.

We compared the above total [^{3}H]-radioactivity data obtained in the rat with those we obtained previously in our human study. To do so, we computed the human brain:blood [^{11}C]-radioactivity concentration at a single time point of 45 min. We chose this time point for comparison as the plasma content of known P-gp substrates (verapamil and metabolites) in human plasma (58.3±13.7% of the total [^{11}C]-radioactivity) at 45 min is close to that observed in the rat plasma at 20 min (46.6±8.7% of the total [^{3}H]-radioactivity). In the absence of CsA, the brain:blood radioactivity ratio in the human (0.79 ± 0.19) and the rat (0.79 ± 0.09) was found to be virtually identical. In addition, at a comparable CsA blood concentration (~3 µM), this brain:blood radioactivity increased in the human and rat to 1.40 ± 0.39 and 1.39 ± 0.20 respectively (Fig. 6). This translates into an increase in the brain:blood radioactivity of 79% and 75% in humans and rats respectively. The human data presented here differ slightly from those published earlier

(Sasongko et al., 2005) because they are ratios of brain:blood radioactivity at a single time point (45 min) while those published earlier are AUCbrain:AUCblood ratios at 45 min.

DISCUSSION

Prior studies have suggested that the combined use of verapamil and CsA as P-gp substrate and inhibitor, respectively, would be ideal for measurement of P-gp transport across the rat and human BBB (for details see (Sasongko et al., 2005). Although the metabolism of verapamil is stereoseletive (Nelson et al., 1988; Bhatti and Foster, 1997) its transport by P-gp is not (Luurtsema et al., 2003). For this reason, and because our measure is brain:blood ratio of radioactivity, the use of the racemic verapamil does not in any way confound the interpretation of our data.

In our study, the lack of difference in brain vascular volume in the absence and presence of CsA indicated that the integrity of the BBB was not compromised by CsA. Our values of the rat brain vascular volume are similar to those previously reported (Brown et al., 1997). Because the vascular content of the brain was only 2~4 %, vascular volume correction of the brain:blood [^{3}H]-radioactivity ratio or the brain:plasma [^{3}H]-verapamil ratio produced only minor changes in the values of these ratios.

The brain:blood total [^{3}H]-radioactivity was significantly increased by CsA (Fig. 2) indicating that CsA is capable of inhibiting P-gp mediated efflux of verapamil associated radioactivity across the rat BBB. CsA inhibited P-gp at the rat BBB with an EC50 of 7.2 μM (Fig. 3A). The maximal increase in brain:blood total [^{3}H]-radioactivity

produced by CsA was comparable to that found by others in the mdr1a/b(-/-) mice

(Hendrikse et al., 1998), indicating that greater than 15 µM blood CsA concentration are

necessary to produce chemical knock out of P-gp at the rat BBB. Since the brain:blood

ratio of [^{3}H]-radioactivity includes verapamil metabolites, we also determined the

contents of [^{3}H]-verapamil and [^{3}H]-verapamil metabolites in both plasma and brain.

In the rat plasma, we detected small quantities of D617, D717, D702 and D703

(Fig. 4), but these concentrations were too low to determine with confidence. In contrast,

the contribution of an unknown metabolite(s) was significant. The identity of this

metabolite(s) is not known, as it did not correspond to any of the standards of verapamil

metabolites in our possession (D617, D717, D702/D703, Fig. 4). Since CYP3A enzymes

are involved in metabolism of both verapamil and CsA, alteration in verapamil

metabolism due to CsA was possible. However, in our study, the plasma verapamil or

metabolite profiles did not change in the presence of CsA, indicating that CsA does not

inhibit the metabolism of verapamil. This observation is consistent with that obtained in

our human study (Sasongko et al., 2005). The brain verapamil and D702/D703 content

increased as blood CsA concentration increased (Fig. 5 inset). In contrast, the brain

content of the unknown metabolite was unaffected by CsA (Fig. 5 inset). These data

indicate that D702/D703 are P-gp substrates, while the unknown metabolite is not. Others

have also shown that D702 and D703 are P-gp substrates (Luurtsema et al., 2005) as are

D617 and D717 (Pauli-Magnus et al., 2000).

Determination of brain and plasma [^{3}H]-verapamil content allowed us to compute

and model the change in brain:plasma [^{3}H]-verapamil ratio with change in CsA blood

concentration. Interestingly CsA inhibited the P-gp mediated efflux of [^{3}H]-verapamil

from the brain with an EC50 (7.9 µM) comparable to that obtained when only total [^{3}H]-radioactivity was considered (7.2 µM). This close agreement between total [^{3}H]-radioactivity and [^{3}H]-verapamil is not surprising as the unknown metabolite is not a P-gp substrate and the only other metabolites found in the brain, D702/D703, were in a small quantity and are P-gp substrates (Luurtsema et al., 2005). Thus, the magnitude of inhibition of their efflux from the brain is unlikely to be different from that of verapamil.

In drug development, mice and rats are frequently used as animal models in preclinical studies. For example, in evaluating the distribution of drugs into the CNS, high affinity P-gp substrates which are efficiently effluxed from the CNS are often discarded from further drug development. It is assumed that such drugs will be efficiently effluxed by P-gp at the human BBB and therefore unlikely to achieve pharmacologically effective concentrations in the human brain. Furthermore, if the candidate drug is found during development to be an excellent P-gp substrate, there is concern that there will be significant drug-drug interactions with such a drug, resulting in increased distribution of the drug into the human brain and significant neurological toxicity. Such an extrapolation from rodents to human is based on the assumption that P-gp activity at the mouse or the rat BBB is representative of that at the human BBB. It is also assumed that the magnitude of P-gp inhibition at the mouse or rat BBB by drugs that are P-gp inhibitors (e.g. CsA, the azoles or the macrolides) is also predictive of inhibition of P-gp at the human BBB. Often, the increase in CNS distribution of the candidate drug in the P-gp knockout mouse is viewed as representative of the "worst" case scenario of a drug-drug interaction where P-gp activity at the BBB is completely ablated.

We propose that the mdr1a/b(-/-) mouse or chemical ablation of P-gp at the rodent BBB overestimate the magnitude of clinically relevant P-gp based interaction at the human BBB. To better predict such drug interactions, the concentration of the P-gp inhibitor used in the rodent studies must be comparable to that observed in the clinic. The data presented above show that at clinical CsA blood concentration (0.13-0.34 μM) (Rowland, 1995) the inhibition of P-gp at the rat BBB is modest and concentrations as high as 7 μM are required to produce significant inhibition (~50%) of P-gp activity at the rat BBB. Given that CsA is one of the most potent inhibitors on the market (relative to the plasma concentrations achieved at therapeutic doses), it is unlikely that other drugs will produce a greater inhibition of P-gp at the rat BBB than CsA at therapeutic concentrations of those drugs.

To date, there are no data available to compare P-gp activity at the rodent and human BBB or to compare between these two species the magnitude of P-gp inhibition at the BBB by a known P-gp inhibitor. The lack of such data is not surprising as hitherto it was impossible to measure P-gp activity at the human BBB. Recently we have developed a noninvasive positron emission tomography (PET) method to determine P-gp at the human BBB and the ability of CsA to inhibit such activity (Sasongko et al., 2005). This method utilizes [^{11}C]-verapamil as the P-gp substrate and CsA as the P-gp inhibitor. In the absence of CsA, the brain:blood radioactivity ratio in the human (0.79 ± 0.19) and the rat (0.79 ± 0.09) was found to be virtually identical. In addition, at a comparable CsA blood concentration (~3 μM), this brain:blood radioactivity increased in the human and rat to 1.40 ± 0.39 and 1.39 ± 0.20 respectively (Fig. 6). This translates into an increase in the brain:blood radioactivity of 79% and 75% in humans and rats respectively.

This remarkable agreement between human and rat BBB P-gp activity, in the absence of CsA, suggests that the rat appears to be a suitable animal model to predict P-gp activity at the human BBB. In addition, at a comparable CsA concentration of 3 µM, the inhibition of P-gp activity at the human and the rat BBB was virtually identical. This agreement was obtained despite the fact that verapamil is metabolized. Therefore, the brain: blood partition coefficient of the non-transported unknown metabolite(s) in the rat and the human must be comparable. This promising agreement between human and rat needs to be confirmed by additional studies in both species with other P-gp inhibitors (e.g. quinidine, the azoles, clarithromycin) and P-gp substrates (e.g. [^{11}C]-loperamide).

The data presented here have important implications for both drug development and the use of CsA as a P-gp inhibitor to overcome the P-gp efflux barrier. In the first, our data suggests that concentrations of CsA much higher (> 15 µM) than that achieved at clinical doses (less than 1µM) will need to be administered to overcome the P-gp efflux barrier in either resistant tumor cells or at the BBB. However, administration of such high doses of CsA to humans would be unethical due to potential nephrotoxicity of CsA (Mourad et al., 1998; Li et al., 2004). To overcome this limitation, more potent third generation P-gp inhibitors such as PSC833 (Valspodar), LY-335979 (Zosuquidar), XR9576 (Tariquidar), VX710 (Biricodar), will need to be utilized. At the same time, the data presented here also suggest that P-gp based drug interactions at the human BBB at therapeutic CsA blood concentrations are unlikely. Second, our data would suggest that the use of the rat as preclinical model to estimate the distribution of drugs (P-gp substrates) across the human BBB appears to be promising. In conclusion, this is the first *in vivo* study to determine an *in vivo* CsA EC50 of inhibition of P-gp transport activity at

the rat BBB. In addition, this is the first time that the rodent and human P-gp activity at

the BBB have been compared in the absence and the presence of an identical blood

concentration of a P-gp inhibitor.

REFERENCES

Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W and de Vries EG (2000) The blood-brain barrier and oncology: new insights into function and modulation. *Cancer Treat Rev* **26**:449-462.

Bart J, Willemsen AT, Groen HJ, van der Graaf WT, Wegman TD, Vaalburg W, de Vries EG and Hendrikse NH (2003) Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. *Neuroimage* **20**:1775-1782.

Bendayan R, Lee G and Bendayan M (2002) Functional expression and localization of P-glycoprotein at the blood brain barrier. *Microsc Res Tech* **57**:365-380.

Bhatti MM and Foster RT (1997) Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. *Biopharm Drug Dispos* **18**:387-396.

Brown RP, Delp MD, Lindstedt SL, Rhomberg LR and Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. *Toxicol Ind Health* **13**:407-484.

Demeule M, Regina A, Jodoin J, Laplante A, Dagenais C, Berthelet F, Moghrabi A and Beliveau R (2002) Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. *Vascul Pharmacol* **38**:339-348.

Fenstermacher JD, Blasberg RG and Patlak CS (1981) Methods for Quantifying the transport of drugs across brain barrier systems. *Pharmacol Ther* **14**:217-248.

Golden PL and Pollack GM (2003) Blood-brain barrier efflux transport. *J Pharm Sci* **92**:1739-1753.

Hendrikse NH, Schinkel AH, de Vries EG, Fluks E, Van der Graaf WT, Willemsen AT, Vaalburg W and Franssen EJ (1998) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. *Br J Pharmacol* **124**:1413-1418.

Kemper EM, Cleypool C, Boogerd W, Beijnen JH and van Tellingen O (2004a) The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. *Cancer Chemother Pharmacol* **53**:173-178.

Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH and van Tellingen O (2003) Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. *Clin Cancer Res* **9**:2849-2855.

Kemper EM, Verheij M, Boogerd W, Beijnen JH and van Tellingen O (2004b) Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. *Eur J Cancer* **40**:1269-1274.

Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. *J Clin Invest* **101**:289-294.

Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M and Sugiyama Y (1997) P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. *J Pharmacol Exp Ther* **283**:574-580.

Li C, Lim SW, Sun BK and Yang CW (2004) Chronic cyclosporine nephrotoxicity: new insights and preventive strategies. *Yonsei Med J* **45**:1004-1016.

Luurtsema G, Molthoff CF, Schuit RC, Windhorst AD, Lammertsma AA and Franssen EJ (2005) Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. *Nucl Med Biol* **32**:87-93.

Luurtsema G, Molthoff CF, Windhorst AD, Smit JW, Keizer H, Boellaard R, Lammertsma AA and Franssen EJ (2003) (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. *Nucl Med Biol* **30**:747-751.

Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P and Schinkel AH (1997) Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. *J Clin Invest* **100**:2430-2436.

Mourad G, Vela C, Ribstein J and Mimran A (1998) Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. *Transplantation* **65**:661-667.

Nelson WL, Olsen LD, Beitner DB and Pallow RJ, Jr. (1988) Regiochemistry and substrate stereoselectivity of O-demethylation of verapamil in the presence of the microsomal fraction from rat and human liver. *Drug Metab Dispos* **16**:184-188.

Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M and Fromm MF (2000) Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. *J Pharmacol Exp Ther* **293**:376-382.

Rowland M, Tozer, TN (1995) Chap. 5, p. 59, in *Clinical pharmacokinetics: concepts and applications*, Williams & Wilkins, Baltimore.

Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC and Unadkat JD (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. *Clin Pharmacol Ther* **77**:503-514.

Schinkel AH, Wagenaar E, Mol CA and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. *J Clin Invest* **97**:2517-2524.

FOOTNOTES

FIGURE LEGENDS

Fig 1. Pseudo steady-state blood CsA concentrations were achieved by 60 min after an i.v. loading dose of CsA followed by an i.v. infusion of CsA. Sixty min after beginning CsA dosing, [^{3}H]-verapamil was administered and the animals were sacrificed at 80 min (i.e. 20 min after [^{3}H]-verapamil administration). The value of n represents the number of animals studied per CsA blood concentration.

Fig 2. Brain: blood total [^{3}H]-radioactivity at increasing pseudo steady-state blood CsA concentration. The average percent increase in brain: blood [^{3}H]-radioactivity for each CsA groups, relative to the absence of CsA, are listed above each histogram bar. These values, determined at 20 min after [^{3}H]-verapamil administration, increased as the pseudo steady-state blood CsA concentration increased; *P<0.05 compared to the control group, 0 μM CsA. The value of n represents the number of animals studied per CsA blood concentration.

Fig 3. (A) The Hill equation was fitted to the percent increase in brain:blood [^{3}H]-radioactivity, expressed relative to that in the control group (absence of CsA) (data shown in Fig. 2). This increase reached a plateau comparable to previously published value in the mdr1a (-/-) mice(Hendrikse et al., 1998) . At an equivalent blood CsA concentration (~3 μM), there is a remarkable agreement between the rat and humans (denoted by the square) in the percent increase in the brain:blood [^{3}H]-radioactivity. The estimates of the the Hill equation parameters were Emax=1290% (7.1%), EC50=7.2 μM (7.3%), and γ=3.8 (22.5%). The values in parenthesis are percent CV of the estimates.

(B) The percent increase in brain: plasma [^{3}H]-verapamil, expressed relative to

that in the control group (absence of CsA), increased as the pseudo steady-state

blood CsA concentration increased. The fitted curve is mathematically described

by the Hill equation with Emax=2630% (7.1%), EC50=7.9 µM (7.1%), and γ=3.7

(19.7%). The values in the parenthesis are percent CV of the estimates.

Fig 4. Metabolic pathways of verapamil in humans. The label is denoted with an

asterisk. Labeled in gray are metabolites not detectable in this study either due to

loss of the label or unavailability of the standard.

Fig 5. At 20 min post [^{3}H]-verapamil administration, the brain [^{3}H]-verapamil or [^{3}H]-

D702/D703 (see inset) content, but not that of the unknown [^{3}H]-metabolite(s),

were significantly affected by CsA. Data are expressed as mean ± SD and were

analyzed by the Student's t test; *P<0.05 compared to the corresponding control

group, 0 µM CsA. The value of n represents the number of animals studied per

CsA blood concentration.

Fig 6. At identical pseudo steady-state CsA blood concentrations of 0 and ~3 µM, the

brain: blood ratios of total [3H]-radioactivity in the rat (gray bars, n=15) are

virtually identical to that previously obtained by us in humans (open bars; n=12)

using PET. The numerical values of the percent increase in brain: blood total

[3H]-radioactivity (relative to the absence of CsA) produced by pseudo steady-

state CsA blood concentrations of ~3 µM are listed above the histogram bars.

The value of n represents the number of animals studied per CsA blood

concentration.

Figure 1.

Figure 2.

Figure 3A.

Figure 3B.

Figure 4.

Figure 5.

Figure 6.